Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-3768|96|2|e201-e212

ISSN： 1755-375X

Source： ACTA OPHTHALMOLOGICA, Vol.96, Iss.2, 2018-03, pp. : e201-e212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spontaneous anatomical improvement on OCT findings in patients with neovascular age‐related macular degeneration without anti‐VEGF treatment

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implementation studies of ranibizumab for neovascular age‐related macular degeneration

By  

ACTA OPHTHALMOLOGICA, Vol. 92, Iss. 1, 2014-02 ,pp. : 98-98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age‐related macular degeneration patients

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

By Mitchell Paul  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1465-1475

Informa Healthcare

Access to resources Recommend Favorite

Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age‐related macular degeneration with and without reticular pseudodrusen: a meta‐analysis

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e105-e110

John Wiley & Sons Inc

Access to resources Recommend Favorite